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Abstract
Background: Epidemiological evidence links Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) to B-cell non-
Hodgkin lymphoma (B-NHL). These B-NHLs, particularly those associated with HCV, may represent a distinct sub-
group with peculiar molecular features, including peculiar expression of microRNAs (miRs).
The aim of the present study was to search for miRs whose level in indolent B-NHL tissues could be associated
with HBV or HCV infection.
Methods: Fourteen formalin fixed paraffin embedded (FFPE) tissues from HBV+, HCV+ and HBV-/HCV- indolent B-
NHL patients were analyzed for levels of 34 selected miRs by quantitative Real-Time PCR. Reactive lymph nodes
(RLNs) from HBV-/HCV- patients were included as non-tumor control. Statistical analysis of output data included
Pearson and Spearman correlation and Mann-Whitney test and were carried out by the STATA software.
Results: MiR-92a was decreased exclusively in HBV-/HCV- B-NHLs, while miR-30b was increased in HBV+ and HCV+
samples, though only the HCV+ achieved full statistical significance. Analysis of a small subset of B-NHLs belonging
to the same histological subtype (Nodal Marginal Zone Lymphoma) highlighted three miRs associated with HCV
infection (miR-223, miR-29a and miR-29b) and confirmed decreased level of miR-92a in HBV-/HCV- samples also
when considering this restricted B-NHL group.
Conclusions: Although caution is needed due to the limited number of analyzed samples, overall the results
suggest that differences at the miR expression level exist between indolent B-NHLs developed in patients with or
without HBV or HCV infection. The identification of three further miRs associated with HCV by analyzing
histologically homogeneous samples suggests that variations of miR levels possibly associated with HBV or HCV
may be obscured by the tissue-specific variability of miR level associated with the different histological subtypes of
B-NHL. Thus, the identification of further miRs will require, in addition to an increased sample size, the comparison
of B-NHL tissues with the same histological classification.
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Background
In addition to liver cancer, increasing evidence has
linked Hepatitis B Virus (HBV) and Hepatitis C Virus
(HCV) to the development of both indolent and aggres-
sive B-cell non-Hodgkin lymphoma (B-NHL). In fact,
most epidemiological studies have identified a positive
association between B-NHL and HCV and HBV infec-
tion [1-4], and a role for both viruses in the pathogen-
esis of B-NHL has been suggested [5-8].
Further support for HCV playing a role in development
of lymphoma has come from reports on the treatment of
HCV infection in B-NHL patients [9-12]. In these studies,
HCV-associated B-NHLs have been reported to be highly
responsive to antiviral therapy: clearance of HCV resulted
in remission of B-NHL, and reappearance of infection was
associated with relapse of the disease. Indeed, these obser-
vations also suggest that (A) HCV is involved not only in
driving development but also in maintaining B-NHL and
(B) HCV-related B-NHLs have specific biological proper-
ties, and consequently molecular features, characterizing
them as a subset distinct from HCV-unrelated B-NHLs,
despite histological similarity [9-12]. However, the
mechanism(s) underlying the role of HCV in the patho-
genesis of B-NHLs, as well as the associated molecular
alterations, remain(s) to be clarified.
In regards to HBV, a potential link with the pathogen-
esis of B-NHL in chronic carriers is provided by its abil-
ity to infect peripheral blood mononuclear cells,
including B lymphocytes [13]. In a recent study, detec-
tion of HBV DNA in B-NHL tissues was more frequent
than in T-cell NHL or other lymphatic system disease
tissues, suggesting that chronic HBV infection in lymph
nodes might be associated with B-NHL [14].
MicroRNAs (miRs) are small, non-coding RNAs emer-
ging as key regulators of several cellular processes, includ-
ing cell growth, development, differentiation and
metabolism. Several hundreds of miRs have been character-
ized and many of them show tissue-specific expression [15].
Although additional mechanisms have been reported, in
vertebrates miRs regulate gene expression mainly at the
post-transcriptional level, by inhibiting translation of target
messenger RNAs by binding to specific, imperfectly com-
plementary, target sites [16-18]. Each miR may regulate
hundreds of potential target mRNAs [19].
Evidence for a role of miRs in the pathogenesis of sev-
eral diseases, including cancer, as well as in the develop-
ment of innovative tools for molecular diagnosis and
prognosis and in the identification of new targets for
therapy has been well documented [18-20].
Studies on Formalin Fixed Paraffin Embedded (FFPE)
tissues have shown that, in contrast with protein coding
mRNAs that are largely degraded, miRs are substantially
unaffected by the standard procedures of FFPE tissue
preparation [21-23]. The possibility to reliably quantify
miRs in slices of FFPE tissues routinely collected for his-
topathological analysis makes miRs excellent candidates
for biomarker discovery using archived FFPE clinical
specimens.
Compelling evidence links miRs to HCV biology. MiR-
122a, highly and specifically expressed in liver but not in B
lymphocytes, binds to two closely spaced target sites in the
5’ noncoding region of the HCV genome, resulting in up-
regulation of viral RNA levels [24]. In addition, though not
documented in B lymphocytes, the potential for HCV to
modulate expression of cellular miRs has been documen-
ted in liver cancer cell lines in vitro [25,26].
Several studies have searched for miRs involved in
development of B-NHL but, to our knowledge, only one
study has investigated the possible influence of HCV on
miR expression in B-NHL, analyzing Splenic Marginal
Zone Lymphoma (SMZL), an indolent B-NHL entity
with peculiar clinical and molecular features [27]. No
study has so far investigated miR expression in other
indolent B-NHLs in patients chronically infected by
HBV or HCV.
The aim of the present study was to identify miRs
whose level in indolent B-NHLs (nodal marginal zone
lymphoma (NMZL), follicular lymphoma (FL), small
lymphocitic lymphoma (SLL)) could be related to HBV
or HCV infection. B-NHLs from patients positive for
HBV or HCV are not as frequent as those from negative
ones: in Italy approximately 1 out of 20 cases of all B-
NHLs may be attributable to HCV infection [3], and
even less if one considers only the indolent fraction;
similar considerations also apply to HBV. Thus, retrieval
of indolent B-NHL FFPE samples from HCV or HBV
positive patients is not an easy task and only major
hematological centers managing large patient numbers
and routinely performing virological diagnosis may pro-
vide such rather rare samples. In the present study, the
archive of the Hematology Center of the “Umberto I”
University Hospital of Sapienza University of Rome,
diagnosing about 50 indolent B-NHL cases per year and
routinely performing virological diagnosis, was searched
for samples from patients positive for HBV or HCV.
Available FFPE tissues, including indolent B-NHLs from
5 HBV positive and 4 HCV positive patients and, as
controls, 5 indolent B-NHLs and 9 reactive lymph nodes
from HBV/HCV negative patients, were then analyzed.




Fourteen indolent B-NHL samples (lymph node biopsies)
had been collected from patients for diagnostic purposes
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before any therapeutic treatment and were classified
according to the WHO Classification by expert patholo-
gists. Patient and sample data are reported in Table 1.
HBV or HCV infection was diagnosed by testing for sero-
logical markers of HBV and HCV by commercial kits.
FFPE samples for histopathological analysis were
obtained by standard procedures.
The study was approved by the Ethical Committee of
the participating Centers. Informed consent was
obtained from the patients. The study is in accordance
with the ethical standards of the institutional commit-
tees and with the Helsinki Declaration.
Nine lymph nodes with minor reactive changes (Reac-
tive Lymph Nodes, RLNs) were also included in the
study as non-neoplastic controls. RLNs were analyzed
exclusively for the level of the 5 miRs (miR-92a, miR-
30b, miR-223, miR-29a and miR-29b) that showed asso-
ciation with presence/absence of HBV or HCV infection
in B-NHL patients.
Total RNA extraction from FFPE tissue sections and
quantification
Total RNA was extracted from FFPE tissue samples by
the miRNeasy FFPE kit (QIAGEN), according to the
manufacturer’s instructions. Further details are reported
in additional file 1. RNA concentration was determined
by the Agilent RNA 6000 Nano Kit on an Agilent 2100
Bioanalyzer (Agilent Technologies), and was calculated
as the mean value from two independent runs. Accurate
RNA concentration estimate was included to avoid nor-
malization of Real-Time PCR data: normalization was
shown to be unnecessary if accurate estimation of RNA
concentration is carried out [28].
miR quantification by Real-Time PCR
The list of assayed miRs is reported in Table 2. A set of
34 miRs was selected for quantification including (A) the
33 most abundantly expressed miRs from the so called
“B-cell miRNome”, reporting miR expression from three
normal B-cell types (naïve, memory and germinal center
centroblasts) and from a Burkitt lymphoma cell line [29]
and (B) miR-26b, which was included despite the very
low level in B-cell miRNome, because of its recently
reported association with HCV in SMZL [27]. Further
details are reported in additional file 1.
miR level was analyzed by Real-Time PCR in 96-well
plates with TaqMan commercial assays (Applied Biosys-
tems). In order to exclude artifacts due to inter-run varia-
tions, all B-NHL samples were assayed for each miR in the
same Real-Time PCR run. Triplicate reactions were carried
out for each miR/sample. Output raw Ct data from Real-
Time PCR were processed by EXCEL functions, including
simple statistical analysis. Processed data were analyzed for
statistical significance by the STATA software.
Results
Reliability of data from FFPE B-NHL tissues
Total RNA extracted from 14 FFPE B-NHLs was analyzed
for 34 selected miRs by commercial Real-Time PCR
assays. Patient and sample data are reported in Table 1,
and the list of assayed miRs in Table 2.
As a first step, the reliability of the obtained Real-Time
PCR data was evaluated. The expression of several miRs is
so exquisitely tissue specific that it is being used to trace
the tissue of origin of metastases from unknown primary
tumors [30-32]. We took advantage of a previous study
reporting the miR levels from 40 normal human tissues,
including lymph node, in which miRs were quantified by
the same Real-Time PCR method used in the present
study; the raw Ct values were available as supplementary
information [33]. In that study, total RNA samples from











1 HBV SLL 66 F
2 HBV FL 49 M
3 HBV SLL 65 M
4 HBV NMZL 73 F
6 HBV FL 55 F
8 HCV NMZL 74 M
9 HCV NMZL 73 F
10 HCV NMZL 66 F
12 HCV FL 60 M
14 Negative FL 72 M
15 Negative SLL 52 F
16 Negative NMZL 62 M
17 Negative NMZL 69 F
18 Negative NMZL 76 M
HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; B-NHL: B-cell Non Hodgkin
Lymphoma; NMZL: Nodal Marginal Zone Lymphoma; FL: Follicular Lymphoma;
SLL: Small Lymphocytic Lymphoma; M: Male; F: Female.
Table 2 List of the assayed 34 miRs.
























* not selected from B-cell miRNome; it was included because found to be
down-regulated in SMZLs from HCV positive patients [27].
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commercial sources, extracted from frozen tissues, were
used.
The average Pearson correlation between the levels of
the 34 miRs in our set of 14 B-NHLs and their levels in
40 human tissues is shown in additional file 2. B-NHLs
exhibited high correlation with lymph node (mean r =
0.76 ± 0.09), low/moderate correlation with thymus and
spleen (mean r = 0.44 ± 0.11 and 0.42 ± 0.09, respectively)
and little if any correlation with the remaining tissues
(mean r < 0.3 ± 0.10). This result suggests good reliability
of our data from FFPE B-NHL tissues, as they show the
expected correlation with data from frozen immune and
other tissues reported in a previous independent study.
In addition, a recent study reported a miR signature
allowing to distinguish NMZLs from FLs: the levels of
miR-221, miR-223 and let-7f, as determined by Real-Time
PCR assays, were increased in NMZLs compared with FLs
[34]. The median expression of these three miRs was com-
pared in our NMZL cases (n = 7) vs. FL cases (n = 4).
Increased miR-221 and miR-223 levels were observed in
NMZLs (4.9 and 4.4 fold, respectively), while similar levels
of let-7f were present in both subtypes (1.1 fold in NMZLs
vs. FLs); however, analysis of let-7f values from individual
samples showed an outlier in one of the four FL cases
(sample ID: 6): by excluding this sample, 3.2 fold higher
level was present in NMZLs vs. the remaining FLs (data
not shown). It can be concluded that the previously
described signature of NMZLs vs. FLs is essentially
observed also in the present study.
miRs differentially expressed in B-NHLs from HBV or HCV
infected vs. uninfected patients
The level of the 34 miRs was then analyzed to search for a
possible differential expression in association with pre-
sence or absence of HBV or HCV infection. B-NHLs from
HBV positive patients (HBV+ B-NHLs) (n = 5) and from
HCV positive patients (HCV+ B-NHLs) (n = 4) were com-
pared with the control B-NHL group from patients nega-
tive for HBV or HCV infection (Ctrl B-NHL) (n = 5).
Most miRs, including miR-26b previously reported to
be associated with HCV in SMZLs [27], did not show sig-
nificant differences, except two of them, miR-92a and
miR-30b, with p-values achieving or approaching statisti-
cal significance (Figure 1A-B; fold vs. control B-NHLs
and p values are summarized in Figure 1C). The median
levels of miR-92a and miR-30b in HBV+ and HCV+
B-NHLs were higher than in control B-NHLs (miR-92a:
6.0 fold and 7.5 fold, respectively; miR-30b: 1.7 fold and
1.8 fold, respectively).
The level of miR-92a and miR-30b was then analyzed in
reactive lymph nodes (RLNs) and compared with the
levels in the B-NHL groups (Figure 1 A-B; folds and
p values are summarized in Figure 1D). The median level
of miR-92a in both HBV+ and HCV+ B-NHLs did not dif-
fer from that observed in RLNs (p = n.s.), while in Ctrl B-
NHLs it was 6.6 fold lower (p = 0.014) (Figure 1 A, D). In
contrast, the median level of miR-30b in HBV+ and HCV
+ B-NHLs, though not reaching statistical significance,
was 1.4 and 1.5-fold higher than in RLNs, respectively,
while in Ctrl B-NHLs it was similar to that observed in
RLNs (Figure 1 B, D).
Correlated expression of miR-30b and miR-92a in B-NHLs
The observed pattern of miR-92a and miR-30b in B-
NHLs and RLNs suggested that the levels of these miRs
could be correlated and, thus, this possibility was for-
mally evaluated by Spearman (r) statistical test.
miR-30b and miR-92a levels were found to be corre-
lated in B-NHLs (r = 0.73; p = 0.003), but not in RLNs
(r = -0.42; p = 0.26). In B-NHL subgroups, statistically
significant and very high correlation of miR-30b and
miR-92a levels was found in Ctrl B-NHLs (r = 0.90; p =
0.037), moderate/high correlation, but not statistically
significant, in the HBV+ B-NHLs (r = 0.70; p = 0.19)
and no significant correlation in the HCV+ B-NHLs
(r = -0.20; p = 0.80), apparently suggesting that correla-
tion is absent in HCV+ B-NHLs. However, examination
of miR-92a and miR-30b levels in individual samples
showed that in the HCV+ group the absence of correla-
tion was due to the individual FL sample, while the
remaining three NMZLs showed a clearly correlated
expression trend (data not shown), suggesting that het-
erogeneity between subtypes may result in decreased
correlation.
To evaluate if histological subtype could be a factor
contributing to the correlated expression of miR-92a
and miR-30b, correlation was also analyzed in B-NHLs
grouped by histological subtype. In SLL, correlation and
statistical significance could not be formally evaluated
because only three samples were available, not allowing
a reliable Spearman test, but examination of miR-92a
and miR-30b levels in individual SLL samples showed a
correlated expression trend (data not shown). In FL,
miR-30b and miR-92a levels were highly correlated,
though not reaching statistical significance (r = 0.80; p
= 0.20), while in NMZL they were very highly correlated
and statistically significant (r = 0.96; p = 0.0005).
Search for miRs associated with HCV infection in NMZLs
As suggested by the above analysis, and also from a theo-
retical point of view, a comparison of histologically
homogeneous samples might be more suitable to detect
virus-associated hallmarks, because this approach would
exclude the variability related to histological differences.
Due to the small number of available samples, this
analysis could be carried out only for NMZLs, and in
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Figure 1 Level of miR-92a and miR-30b in HBV+ B-NHL, HCV+ B-NHL, Ctrl B-NHL and RLN groups. Box-plot representation of the level of
miR-92a (A) and miR-30b (B) in HBV+ B-NHL, HCV+ B-NHL, Ctrl B-NHL and RLN sample groups. HBV+ B-NHL: B-NHLs from HBV positive patients;
HCV+ B-NHL: B-NHLs from HCV positive patients; Ctrl B-NHL: control B-NHLs from patients negative for both HBV and HCV. The level is reported
as 2-Ct values. p values < 0.1 are reported, and those < 0.05 are shown in bold. C and D: summary of fold-change (vs. reference Ctrl B-NHL and
RLN, respectively) and p-value (Mann-Withney test). Fold-change was calculated as ratio between median level of each group vs. median level of
the reference group.
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relation with HCV but not HBV: three NMZLs from
HCV-positive patients (HCV+ NMZLs) were compared
with three control NMZLs from HCV-negative patients
(Ctrl NMZLs).
Four out of the 34 assayed miRs showed a statistically
significant different level between the groups (Figure 2):
in HCV+ NMZLs, median levels of both miR-223 and
miR-92a were 3.8-fold higher than in Ctrl NMZLs (p =
0.049 for both miRs), while miR-29a and miR-29b were
1.6- and 1.2-fold lower, respectively, than in Ctrl
NMZLs (p = 0.049 for both) (Figure 2 A-B).
Then, the levels of miR-223, miR-92a, miR-29a and
miR-29b were determined in nine RLN controls and
compared with those in HCV+ and Ctrl NMZLs.
miR-223 level in HCV+ NMZLs was 6.7-fold higher than
in RLNs (p = 0.013), while in Ctrl NMZLs it did not show
a significant difference (p = 0.78) (Figure 2 A, C): thus, miR-
223 was up-regulated in HCV+ but not in Ctrl NMZLs.
Figure 2 Level of miR-223, miR-92a, miR-29a and miR-29b in HCV+ NMZL, Ctrl NMZL and RLN groups. A: box-plot representation of the
level of miR-223, miR-92a, miR-29a and miR-29b in HCV+ NMZL, Ctrl NMZL and RLN sample groups. HCV+ NMZL: NMZLs from HCV positive
patients; Ctrl NMZL: NMZLs from HCV negative patients; RLN: non-neoplastic Reactive Lymph Nodes. The level is reported as 2-Ct values. p values
<0.1 are reported, and those < 0.05 are shown in bold. B and C: summary of fold-change (vs. reference Ctrl NMZLs and RLNs, respectively) and
p-value (Mann-Whitney test). Fold-change was calculated as ratio between median level of each group vs. median level of the reference group.
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miR-92a level in HCV+ NMZLs showed no significant
difference versus RLNs (p = 0.93) while in Ctrl NMZLs
it showed a 2.7-fold lower level than in RLNs (tending
to significance, p = 0.079) (Figure 2), a result similar to
that obtained by the above analysis of all available sam-
ples, in which B-NHLs negative for HBV and HCV (that
included the three NMZLs of the present comparison)
showed lower miR-92a levels than RLNs (see previous
paragraphs and Figure 1).
Finally, miR-29a and miR-29b levels in both HCV+
and Ctrl NMZLs were significantly higher than in RLNs
(p = 0.013 in both comparisons): however, the degree of
up-regulation in the HCV+ group was significantly
lower than in the HCV- Ctrl group (miR-29a: 10-fold vs.
16-fold respectively, p = 0.0495; miR-29b: 103-fold vs.
123-fold respectively, p = 0.0495) (Figure 2 A, C).
Then, the comparison versus RLNs of miRs up-regu-
lated in HCV+ NMZLs (miR-223, miR-92a, miR-29a and
miR-29b) was extended to the whole group of fourteen
B-NHLs. In contrast to miR-223 and miR-92a, showing
no significant differences, the increased miR-29a and
miR-29b level observed in both HCV+ and Ctrl NMZLs
was common to all other B-NHLs too: median level in
B-NHLs was significantly higher than in RLNs (miR-29a:
11-fold, p = 0.002; miR-29b: 106-fold, p = 0.0002) (data
not shown).
In addition, correlation analysis by the Spearman test
showed that the miR-29a and miR-29b levels were highly
correlated in B-NHLs (r = 0.916, p < 0.0001), but not in
RLNs (r = -0.583, p = 0.099). In B-NHL histological sub-
groups, high correlation values were found in the HBV+
and Ctrl B-NHL subgroups (r = 0.80 in both groups, albeit
not reaching statistical significance: p = 0.10 in both) but
not in the HCV+ subgroup (r = 0.20, p = 0.80). The lack
of statistical significance in individual B-NHL subgroups,
but not in the whole group of B-NHLs, is likely an effect
of the small sample size of the individual subgroups.
Discussion
FFPE tissues have been reported in previous studies to be
as suitable as frozen tissues for quantification of miR
expression: this finding was confirmed in the present
study. The results of the correlation analysis of Real-Time
PCR data from our set of FFPE B-NHLs and data pre-
viously reported from 40 different frozen tissues showed
the expected correlations: miR profiles from B-NHLs were
highly correlated with profiles from lymph node tissue, to
a lesser extent with spleen and thymus and not at all with
the remaining 37 tissues. In addition, a previously
described miR signature distinguishing NMZLs from FLs
was observed also in samples of the present study.
Association of miR-26b with HCV in SMZLs was
reported in a previous study [27]. No significant association
of miR-26b with HCV was observed in our set of B-NHLs,
that included NMZLs, FLs, SLLs, but not SMZLs. In
another lymphoma subtype, Diffuse Large B Cell Lym-
phoma (DLBCL), it has been reported that its location is an
important factor in determining the differential expression
of miRNAs: in fact, two miRs (miR-17-5p and miR-127)
showed significant level differences depending on the site
of presentation (central nervous system, testicular, nodal)
[35]. Thus, it is possible that HCV may affect miR-26b in
SMZL due to the splenic localization of that B-NHL.
Compared with Ctrl B-NHLs, the level of miR-92a and
miR-30b appeared to be increased in HBV+ and HCV+
B-NHLs. However, compared with non-neoplastic RLNs
the miR-92a levels appeared unchanged in the HBV+
and HCV+ groups and decreased in B-NHLs negative
for HBV and HCV, suggesting down-regulation in Ctrl
B-NHLs, rather than up-regulation in HBV+ and HCV+
B-NHLs (Figure 1A). In contrast, the level of miR-30b
in HBV+ and HCV+ B-NHLs was increased also with
respect to RLNs; thus, miR-30b up-regulation appears to
be associated with HBV and HCV, though the relevance
of this result is limited by the lack of significance in the
comparison with RLNs, a result influenced by the small
level of variation and by the limited number of available
samples.
Although miR-92a is usually up-regulated in tumors
compared to normal tissues [36,37], our finding is not
surprising because miR-92a down-regulation in tumors
has also been described, e.g. in breast cancer in associa-
tion with aggressive features and increased tumor
macrophage infiltration [38]. This underscores the
importance of carefully studying miR expression in spe-
cific tumor types, because a miR can show different
expression levels in different tumor types.
The unchanged level of miR-92a in HBV+ and HCV+
B-NHLs, as opposed to the decrease in HBV-/HCV- B-
NHLs, suggests either that HBV and HCV infection
might play an opposite, compensatory role on miR-92a
level or that in these patients B-NHL develops in the
absence of miR-92a down-regulation.
Levels of miR-92a and miR30b were found to be highly
correlated in B-NHLs but not in RLNs, suggesting that
the correlation between these miRs is a tumor-associated
alteration. This finding implies that the observed levels of
miR-92a in HBV+ B-NHLs, HCV+ B-NHLs and RLNs,
though similar, actually result from different underlying
mechanisms. The correlation of miR-92a and miR-30b
was found to be very high and significant in Ctrl
B-NHLs, but was less pronounced in HBV+ and HCV+
B-NHLs, suggesting these viral infections may play some
role in modifying the correlated expression of these miRs.
Overall, even considering the limited number of avail-
able samples, the results appear to suggest that some dif-
ferences at the miR level indeed exist between indolent
B-NHLs from patients with or without HBV or HCV
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infection. However, they were difficult to detect, mainly
because of the small sample size, that negatively affected
the statistical significance, but likely also because of the
association of miR expression with tissue specificity and
differentiation [39]. Indeed, the different miR levels asso-
ciated with different histological subtypes likely represent
a bias able to obscure small changes associated with HBV
or HCV infection, preventing the identification of those
miRs actually influenced by these viral infections, but
whose variation is smaller than that observed among dif-
ferent histological subtypes.
Consistent with this view, analysis of B-NHL tissues
belonging to the same histological subtype (NMZL) led
to identification of four miRs (miR-92a, miR-223, miR-
29a and miR-29b) that showed significantly different
levels between HCV+ and HCV- cases, despite the small
sample size. Actually, the comparison with RLNs sug-
gested down-regulation of miR-92a in Ctrl NMZLs,
rather than up-regulation in HCV+ NMZLs, confirming
also in the restricted NMZL subgroup what observed
analyzing all B-NHL cases (see above).
In contrast to miR-92a, miR-223 was up-regulated in
HCV+ NMZLs: the level was 3.8-folds higher than in
Ctrl NMZLs and 6.7-folds higher than in RLNs, suggest-
ing a role for HCV in increasing the miR-223 level.
MiR-29a and miR-29b were up-regulated in both HCV+
and Ctrl NMZLs compared to RLNs, and extension of the
analysis to all available B-NHLs showed that up-regulation
of these miRs was common to the whole B-NHL group, a
feature also shared with another lymphoid malignancy,
chronic lymphocytic leukemia [40]. However, up-regula-
tion in the HCV+ NMZLs was significantly lower than in
the Ctrl NMZLs, suggesting a role for HCV in “dampen-
ing” the up-regulation. This hypothesis is supported by the
observation that miR-29 was down-regulated by HCV
infection in hepatocytes [41], and a similar effect might
also occur in HCV-infected cells other than hepatocytes,
such as B-cells.
Intriguingly, both miR-223 and miR-29a, associated
with HCV in the present study, have been reported to
be activated by a common transcription factor, CEBPA
[42-45]. The possible interaction of HCV with this fac-
tor, if any, is expected to be complex, because CEBPA
leads to increased levels of both miR-223 and miR-29a,
while HCV was associated with increased miR-223 but
decreased miR-29a.
Conclusions
Although the significance is hampered by the limited
number of available samples, the present study suggests
the existence of differences at the miR expression level
between indolent B-NHLs developed in patients with or
without HBV or HCV infection.
Analysis of histologically heterogeneous B-NHLs
showed that miR-30b was increased in HBV+ and HCV
+ cases, while miR-92a was decreased in cases negative
for these infections; the levels of these miRs proved to
be correlated in B-NHLs but not in RLNs.
Analysis of a small subset of B-NHLs with the same his-
tological subtype classification (NMZL) showed associa-
tion of four miRs (miR-92a, miR223, miR-29a and miR-
29b) with HCV infection. Though caution is needed due
to the limited number of analyzed samples, nevertheless
this result suggests that heterogeneity of histological sub-
types may represent an obstacle for the identification of
miRs possibly influenced by HBV or HCV. Thus, further
studies aiming at identifying miRs associated with HBV
and HCV in B-NHLs will require both a larger sample size
and the comparison of B-NHL tissues with the same histo-
logical subtype classification.
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